Andrographolide suppresses <scp>RANKL</scp>‐induced osteoclastogenesis <i>in vitro</i> and prevents inflammatory bone loss <i>in vivo</i>

Abstract

AP suppressed RANKL-induced osteoclastogenesis through attenuating NF-κB and ERK/MAPK signalling pathways in vitro, thus preventing bone loss in vivo. These data indicated that AP is a promising natural compound for the treatment of osteoclast-related bone diseases.